Outcomes of a Standardized Triple‐Drug Regimen for the Treatment of Nontuberculous Mycobacterial Pulmonary Infection
Authors:
- Maeve P. MurrayMMMaeve P. Murray
- Ian F. LaurensonILIan F. Laurenson
- Adam T. HillAHAdam T. Hill
Open Access
- 15 July 2008
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (2) , 222-224
Abstract
The treatment of fibrocavitatory pulmonary infection due to Mycobacterium avium complex and Mycobacterium malmoense poses a challenge. This study assessed microbial, inflammatory, radiographic, and clinical outcomes for a standardized 24-month triple-drug regime. Following treatment completion, all patients had fewer symptoms, experienced a reduction in systemic inflammation, and had negative sputum mycobacterial culture results.Keywords
This publication has 5 references indexed in Scilit:
- An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial DiseasesAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Treatment of Pulmonary Disease Caused by Mycobacterium avium ComplexInternal Medicine, 2003
- First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutolThorax, 2001
- Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999Thorax, 2000
- Mycobacterium Avium Disease: Progress at LastAmerican Journal of Respiratory and Critical Care Medicine, 1996